Dexcom Names Masimo Exec Jon Coleman as CCO

Dexcom has appointed Jon Coleman as its new chief commercial officer (CCO). Coleman will lead the company’s global commercial organization, including global sales, marketing, and customer experience.

Coleman was an executive officer at Masimo, where he had roles of increasing responsibility during his fifteen-year tenure. This includes serving as president of Masimo’s commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams.

He also worked in significant roles at Pfizer’s Consumer Healthcare business, leading as VP and GM of Canada and the Caribbean region after several years or regional leadership in Asia and Latin America.

“Jon has demonstrated the ability to lead organizations through the complexities of global healthcare with consistently strong performance across a variety of sectors and channels,” said Kevin Sayer, chairman, president and CEO at Dexcom. “This broad experience across market segments and regions provides a great fit as we look to capitalize on Dexcom’s incredible growth opportunity.”

“Dexcom’s commitment to drive innovation in glucose biosensing and its unique long-term growth opportunity make the chief commercial officer role an incredible opportunity,” added Coleman. “I am excited to lead this great team at a key point in the company’s history and execute on the company’s ambitious vision to empower greater health around the world.”